- Home
- CAN vs BMEA Comparison
CAN vs BMEA Comparison
Compare CAN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- BMEA
- Stock Information
- Founded
- CAN 2013
- BMEA 2017
- Country
- CAN Singapore
- BMEA United States
- Employees
- CAN N/A
- BMEA N/A
- Industry
- CAN Semiconductors
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- BMEA Health Care
- Exchange
- CAN Nasdaq
- BMEA Nasdaq
- Market Cap
- CAN 384.3M
- BMEA 65.8M
- IPO Year
- CAN 2019
- BMEA 2021
- Fundamental
- Price
- CAN $0.71
- BMEA $1.66
- Analyst Decision
- CAN Strong Buy
- BMEA Strong Buy
- Analyst Count
- CAN 6
- BMEA 10
- Target Price
- CAN $2.67
- BMEA $22.30
- AVG Volume (30 Days)
- CAN 28.9M
- BMEA 2.3M
- Earning Date
- CAN 08-14-2025
- BMEA 07-30-2025
- Dividend Yield
- CAN N/A
- BMEA N/A
- EPS Growth
- CAN N/A
- BMEA N/A
- EPS
- CAN N/A
- BMEA N/A
- Revenue
- CAN $317,009,000.00
- BMEA N/A
- Revenue This Year
- CAN $160.28
- BMEA N/A
- Revenue Next Year
- CAN $35.68
- BMEA N/A
- P/E Ratio
- CAN N/A
- BMEA N/A
- Revenue Growth
- CAN 65.68
- BMEA N/A
- 52 Week Low
- CAN $0.53
- BMEA $1.29
- 52 Week High
- CAN $3.27
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- CAN 53.84
- BMEA 42.36
- Support Level
- CAN $0.58
- BMEA $1.63
- Resistance Level
- CAN $0.62
- BMEA $3.08
- Average True Range (ATR)
- CAN 0.05
- BMEA 0.23
- MACD
- CAN 0.01
- BMEA -0.08
- Stochastic Oscillator
- CAN 75.53
- BMEA 5.33
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.